<DOC>
	<DOCNO>NCT00818389</DOCNO>
	<brief_summary>The purpose study compare effectiveness lithium combine riluzole riluzole combine placebo people amyotrophic lateral sclerosis .</brief_summary>
	<brief_title>Study Investigate Safety Efficacy Lithium Volunteers With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) rare , neurodegenerative disorder result progressive waste paralysis voluntary muscle . In double blind , randomize , placebo-controlled clinical trial , researcher evaluate safety effectiveness drug lithium give combination riluzole , drug commonly use treat ALS , compare placebo give combination riluzole . Approximately 250 participant recruit multiple center , US Canada , belong Northeast ALS Consortium ( NEALS ) Canadian ALS Clinical Trials Research Network ( CALS ) . Enrollment occur stage . Initially 84 participant enrol trial . An interim analysis use available data occur 84th participant enrol . During time , Data Safety Monitoring Board ( DSMB ) appoint National Institutes Health ( NIH ) may decide stop trial efficacy futility reason stop enrollment request follow-up continue 84 participant already enrol trial , DSMB may decide continue enrollment . Participants randomize one two arm study . Arm one receive lithium riluzole . Arm two receive riluzole placebo ( inactive substance ) . All participant receive riluzole . After screen randomization , participant follow every 4 week first 12 week . Subsequent in-person visit occur every 8 week final visit week 52 . Between in-person visit , telephone interview take place every 4 week administer Amyotropic Lateral Sclerosis Functional Rating Scaleâ€”Revised ( ALSFRS-R ) questionnaire . A follow-up telephone interview occur week 56 ( study medication ) review adverse event . The primary outcome measure disease progression measure ALSFRS-R questionnaire . Participants randomize placebo whose disease progress crossed lithium remain period study ( 52 week total ) . Duration study participant 56 week include 52 week treatment followup telephone interview week 56 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Familial sporadic ALS Participants diagnose laboratory support probable , clinically possible , probable definite ALS accord World Federation Neurology Revised El Escorial criterion Disease duration symptom onset great 36 month Screening Visit Age 18 year older Capable provide informed consent comply trial procedure On stable dose riluzole 50 milligram ( mg ) twice per day ( bid ) least 30 day prior screen Vital capacity ( VC ) equal 60 % predict normal value gender , height age Screening Visit Creatinine &lt; 1.5 milligram per deciliter ( mg/dl ) [ 133 micromoles per liter ( umol/L ] Participants maintain thyroid medication must euthyroid least 3 month Screening Visit . Participants psoriasis must inactive disease least 30 day Screening Visit . Women must able become pregnant ( e.g. , post menopausal least one year , surgically sterile , practice adequate birth control method ) duration study . Women childbearing potential must negative serum pregnancy test Screening Visit nonlactating . Geographic accessibility study site History know sensitivity intolerability lithium relate compound Prior exposure lithium within 90 day Screening Visit Exposure investigational agent within 30 day Screening Visit Participants malnourish , dehydrate sodiumfree diet exclude due potential side effect lithium carbonate Use digoxin iodide salt [ e.g . calcium iodide , hydrogen iodide ( hydriodic acid ) , iodide , iodinate glycerol ( Organidin ) , iodine , potassium iodide ( SSKI ) , sodium iodide supplementation beyond table salt ] Presence follow clinical condition : Substance abuse within past year ; Unstable cardiac , pulmonary , renal , hepatic , endocrine , hematologic , active malignancy infectious disease ; autoimmune deficiency syndrome ( AIDS ) AIDSrelated complex ; Clinically active psoriasis within 30 day Screening Visit ; Unstable psychiatric illness define psychosis ( hallucination delusion ) untreated major depression within 90 day Screening Visit ; Screening serum creatinine great equal 1.5 mg/dL ( 133 umol/L ) , thyroid stimulate hormone ( TSH ) &gt; 20 % upper limit ; Presence clinically significant conduction abnormality electrocardiogram ( ECG ) ; Lactating positive serum pregnancy test Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Amyotrophic lateral sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>Lou Gehrig 's disease</keyword>
	<keyword>riluzole</keyword>
	<keyword>lithium</keyword>
	<keyword>neurodegeneration</keyword>
</DOC>